http://orcid.org/0000-0002-3111-2385
References
- For selected reviews about diverse biological activities of dihydrobenzoxazinones, see: (a) Macías, F. A.; Marín, D.; Oliveros-Bastidasab, A.; Molinillo, J. M. G. Nat. Prod. Rep. 2009, 26, 478–489. (b) Ilaš, J.; Anderluh, P. Š.; Dolenc, M. S.; Kikelj, D. Tetrahedron 2005, 61, 7325–7348. (c) Osbourn, A. E.; Lanzotti, V. Plant-Derived Natural Products: Synthesis, Function, and Application; Springer: Heidelberg, 2009. (d) Holsworth, D.; Park, W., U.S. Patent 2009311318 (A1), Substituted (S)-benzoxazinones, Dec. 17, 2009; (e) Su, S.-S. Michael, Pyruvate kinase Activators for Use for Increasing Lifetime of the Red Blood Cells and Treating Anemia Patent WO 2012151440, Nov. 8, 2012. (f) Yoon, G.; Jeong, H. J.; Kim, J. J.; Cheon, S. H. Arch. Pharm. Res. 2008, 31, 989–994.
- (a) Lu, L.-Q.; Li, Y.; Junge, K.; Beller, M. J. Am. Chem. Soc. 2015, 137, 2763–2768. (b) Núñez-Rico, J. L.; Vidal-Ferran, A. Org. Lett. 2013, 15, 2066–2069. (c) Chen, Q.-A.; Gao, K.; Duan, Y.; Ye, Z.-S.; Shi, L.; Yang, Y.; Zhou, Y. G. J. Am. Chem. Soc. 2012, 134, 2442–2448. (d) Chen, Q.-A.; Chen, M.-W.; Yu, C.-B.; Shi, L.; Wang, D.-S.; Yang, Y.; Zhou, Y.-G. J. Am. Chem. Soc. 2011, 133, 16432–16435. (e) Xue, Z.-Y.; Jiang, Y.; Peng, X.-Z.; Yuan, W.-C.; Zhang, X.-M. Adv. Synth. Catal. 2010, 352, 2132–2136. (f) Malkov, A. V.; Vranková, K.; Stončius, S.; Kočovský, P. J. Org. Chem. 2009, 74, 5839–5849. (g) Lou, H.; Wang, Y.; Jin, E.; Lin, X. J. Org. Chem. 2016, 81, 2019–2026. (h) Zhang, X.; Xu, B.; Xu, M.-H. Org. Chem. Front. 2016, 3, 944–948. (i) Huo, C.; Dong, J.; Su, Y.; Tang, J.; Chen, F. Chem. Comm. 2016, 52, 13341–13344. (j) Zhao, L.; Wei, J.; Lu, J.; He, C.; Duan, C. Angew. Chem. Int. Ed. 2017, 56, 8692–8696.
- (a) Kim, H. J.; Shin, E.-K.; Chang, J.-Y.; Kim, Y.; Park, Y. S. Tetrahedron Lett. 2005, 46, 4115–4117. (b) Kim, H. J.; Kim, Y.; Choi, E. T.; Lee, M. H.; No, E. S.; Park, Y. S. Tetrahedron 2006, 62, 6303–6311. (c) Kim, Y.; Lee, M. H.; Choi, E. T.; No, E. S.; Park, Y. S. Heterocycles 2007, 71, 5–11.
- (a) Koh, K.; Durst, T. J. Org. Chem. 1994, 59, 4683–4686. (b) Koh, K.; Ben, R. N.; Durst, T. Tetrahedron Lett. 1994, 35, 375–378. (c) O’Meara, J. A.; Gardee, N.; Jung, M.; Ben, R. N.; Durst, T. J. Org. Chem. 1998, 63, 3117–3119. (d) Ben, R. N.; Durst, T. J. Org. Chem. 1999, 64, 7700–7706.
- In references 3 and 4, it was established that (αS)-products were provided in the substitution of both 1 and 2 with various amine nucleophiles. The absolute configuration of 3–14 is assigned by analogy. The S configuration of (S)-3 was confirmed after the conversion to 8 using H2 with Pd/C, by the comparison of chiral stationary phase-HPLC retention times and elution order with the reported values of 8 in ref. 2. ref. 2a-d.
- Dai, W.-M.; Wang, X.; Ma, C. Tetrahedron 2005, 61, 6879–6885.
- Zidar, N.; Kikelj, D. Tetrahedron 2008, 24, 5756–5761.
- (a) Lee, Y. M.; Park, Y. S. Heterocycles 2009, 73, 2233–2244. (b) Lee, Y. M.; Kang, K. H.; Min, H.-M.; Lim, H. J.; Park, E.-H.; Park, Y. S. Arkivoc 2010, ii, 1–15. (c) Kim, Y.; Park, K. J.; Choi, Y. S.; Lee, M.; Park, Y. S. Bull. Korean Chem. Soc. 2013, 34, 2531–2534.